615 related articles for article (PubMed ID: 19695400)
1. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting.
Yoon NM; Cavaghan MK; Brunelle RL; Roach P
Clin Ther; 2009 Jul; 31(7):1511-23. PubMed ID: 19695400
[TBL] [Abstract][Full Text] [Related]
2. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.
Barnett AH; Burger J; Johns D; Brodows R; Kendall DM; Roberts A; Trautmann ME
Clin Ther; 2007 Nov; 29(11):2333-48. PubMed ID: 18158075
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.
Moretto TJ; Milton DR; Ridge TD; Macconell LA; Okerson T; Wolka AM; Brodows RG
Clin Ther; 2008 Aug; 30(8):1448-60. PubMed ID: 18803987
[TBL] [Abstract][Full Text] [Related]
4. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
Buse JB; Bergenstal RM; Glass LC; Heilmann CR; Lewis MS; Kwan AY; Hoogwerf BJ; Rosenstock J
Ann Intern Med; 2011 Jan; 154(2):103-12. PubMed ID: 21138825
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study.
Inagaki N; Atsumi Y; Oura T; Saito H; Imaoka T
Clin Ther; 2012 Sep; 34(9):1892-908.e1. PubMed ID: 22884767
[TBL] [Abstract][Full Text] [Related]
6. Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years.
Norwood P; Liutkus JF; Haber H; Pintilei E; Boardman MK; Trautmann ME
Clin Ther; 2012 Oct; 34(10):2082-90. PubMed ID: 23031623
[TBL] [Abstract][Full Text] [Related]
7. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
Buse JB; Klonoff DC; Nielsen LL; Guan X; Bowlus CL; Holcombe JH; Maggs DG; Wintle ME
Clin Ther; 2007 Jan; 29(1):139-53. PubMed ID: 17379054
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus.
Sheffield CA; Kane MP; Busch RS; Bakst G; Abelseth JM; Hamilton RA
Endocr Pract; 2008 Apr; 14(3):285-92. PubMed ID: 18463034
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes using long-term combination therapy with insulin glargine and exenatide in patients with type 2 diabetes mellitus.
Levin PA; Mersey JH; Zhou S; Bromberger LA
Endocr Pract; 2012; 18(1):17-25. PubMed ID: 21742605
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes of concomitant therapy of exenatide twice daily and basal insulin in patients with type 2 diabetes mellitus: a retrospective database analysis in the United States.
Pawaskar M; Li Q; Hoogwerf BJ; Reynolds MW; Lee LJ; Fonseca V
Endocr Pract; 2012; 18(5):700-11. PubMed ID: 22982784
[TBL] [Abstract][Full Text] [Related]
11. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
Heine RJ; Van Gaal LF; Johns D; Mihm MJ; Widel MH; Brodows RG;
Ann Intern Med; 2005 Oct; 143(8):559-69. PubMed ID: 16230722
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of exenatide administered before the two largest daily meals of Latin American patients with type 2 diabetes.
Forti A; Garcia EG; Yu MB; Jimenez MC; Brodows RG; Oliveira JH
Curr Med Res Opin; 2008 Sep; 24(9):2437-47. PubMed ID: 18662495
[TBL] [Abstract][Full Text] [Related]
13. Glucagon-like peptide-1 analog and insulin combination therapy in the management of adults with type 2 diabetes mellitus.
Tzefos M; Olin JL
Ann Pharmacother; 2010; 44(7-8):1294-300. PubMed ID: 20530705
[TBL] [Abstract][Full Text] [Related]
14. Long-term effects of adding exenatide to a regimen of metformin and/or sulfonylurea in type 2 diabetes: an uncontrolled, open-label trial in Hungary.
Iványi T; Fövényi J; Faludi P; Han J; Macconell L; Wille S; Kiljanski J
Clin Ther; 2012 Jun; 34(6):1301-13. PubMed ID: 22608106
[TBL] [Abstract][Full Text] [Related]
15. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.
Blevins T; Pullman J; Malloy J; Yan P; Taylor K; Schulteis C; Trautmann M; Porter L
J Clin Endocrinol Metab; 2011 May; 96(5):1301-10. PubMed ID: 21307137
[TBL] [Abstract][Full Text] [Related]
16. [Metabolic control and weight loss in patients with obesity and type 2 diabetes mellitus, treated with exenatide].
Pujante Alarcón P; Hellín Gil MD; Román LM; Ferrer Gómez M; García Zafra MV; Tébar Massó J
Med Clin (Barc); 2012 Dec; 139(13):572-8. PubMed ID: 22209597
[TBL] [Abstract][Full Text] [Related]
17. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.
Buse JB; Henry RR; Han J; Kim DD; Fineman MS; Baron AD;
Diabetes Care; 2004 Nov; 27(11):2628-35. PubMed ID: 15504997
[TBL] [Abstract][Full Text] [Related]
18. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
[TBL] [Abstract][Full Text] [Related]
19. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.
DeFronzo RA; Ratner RE; Han J; Kim DD; Fineman MS; Baron AD
Diabetes Care; 2005 May; 28(5):1092-100. PubMed ID: 15855572
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Exenatide Plus Pioglitazone Vs Basal/Bolus Insulin in T2DM Patients With Very High HbA1c.
Abdul-Ghani M; Migahid O; Megahed A; DeFronzo RA; Zirie M; Jayyousi A
J Clin Endocrinol Metab; 2017 Jul; 102(7):2162-2170. PubMed ID: 28324038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
